Egbert Frederik Smit
#124,938
Most Influential Person Now
Egbert Frederik Smit's AcademicInfluence.com Rankings
Egbert Frederik Smitmedical Degrees
Medical
#1979
World Rank
#2367
Historical Rank
Oncology
#106
World Rank
#110
Historical Rank
Download Badge
Medical Biology
Egbert Frederik Smit's Degrees
- PhD Biomedical Sciences University of Amsterdam
- Masters Biomedical Sciences University of Amsterdam
- Bachelors Biomedical Sciences University of Amsterdam
Why Is Egbert Frederik Smit Influential?
(Suggest an Edit or Addition)Egbert Frederik Smit's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. (2003) (2937)
- Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. (2015) (1151)
- Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer (2012) (1151)
- Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer (2010) (841)
- Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial (2019) (836)
- Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial (2002) (814)
- Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. (2016) (768)
- RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics (2015) (620)
- Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. (2007) (573)
- Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. (2008) (537)
- Pan-cancer whole-genome analyses of metastatic solid tumours (2018) (526)
- Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids (2018) (506)
- Long‐term expanding human airway organoids for disease modeling (2019) (488)
- Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. (2017) (433)
- A Genomics-Based Classification of Human Lung Tumors (2013) (403)
- Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. (2014) (360)
- Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975. (2003) (348)
- Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer. (2012) (327)
- Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. (2020) (325)
- Clinical prediction model to characterize pulmonary nodules: validation and added value of 18F-fluorodeoxyglucose positron emission tomography. (2005) (318)
- Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. (2015) (318)
- Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. (2012) (313)
- Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. (2016) (297)
- Tepotinib in Non‐Small Cell Lung Cancer with MET Exon 14‐Skipping Mutations or MET Amplification: a Phase 2 Trial in Progress: OA06 (2018) (294)
- Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop (2010) (289)
- Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers (2019) (287)
- Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer (2018) (280)
- Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. (2002) (277)
- Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. (2014) (276)
- Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. (2005) (267)
- Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-d-glucose and positron emission tomography: an overview of different analytical methods (2000) (264)
- Stage I-II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis. (2013) (260)
- Neurobehavioral status and health-related quality of life in newly diagnosed high-grade glioma patients. (2001) (237)
- 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. (2014) (223)
- Repeatability of Radiomic Features in Non-Small-Cell Lung Cancer [18F]FDG-PET/CT Studies: Impact of Reconstruction and Delineation (2016) (214)
- Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy--a phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group. (2000) (212)
- Swarm Intelligence-Enhanced Detection of Non-Small-Cell Lung Cancer Using Tumor-Educated Platelets (2017) (211)
- Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. (2010) (208)
- Erlotinib for Frontline Treatment of Advanced Non–Small Cell Lung Cancer: a Phase II Study (2006) (207)
- Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG uptake in non-small cell lung cancer PET studies (2011) (188)
- Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients. (2014) (187)
- Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. (2009) (173)
- Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer. (2014) (173)
- Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. (2006) (172)
- Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography. (2011) (171)
- The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC (2017) (170)
- Multidrug resistance related molecules in human and murine lung. (2002) (168)
- Repeatability of 18F-FDG Uptake Measurements in Tumors: A Metaanalysis (2012) (166)
- Oral nutritional supplements containing (n-3) polyunsaturated fatty acids affect the nutritional status of patients with stage III non-small cell lung cancer during multimodality treatment. (2010) (165)
- A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. (1998) (163)
- Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. (2011) (159)
- Single-agent oral etoposide for elderly small cell lung cancer patients. (1990) (158)
- Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. (2021) (158)
- An Immune Response Enriched 72-Gene Prognostic Profile for Early-Stage Non–Small-Cell Lung Cancer (2009) (157)
- Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy (2009) (157)
- Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study. (2006) (156)
- Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. (2009) (155)
- Outcome of bronchial carcinoma in situ. (2000) (155)
- Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. (2009) (154)
- Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer (2015) (153)
- Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955). (2000) (153)
- The natural course of preneoplastic lesions in bronchial epithelium. (2005) (151)
- Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET. (2002) (151)
- Definition of synchronous oligo-metastatic non-small cell lung cancer - a consensus report. (2019) (148)
- Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer. (2006) (147)
- Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort (2015) (140)
- Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study (2003) (139)
- Expression of X-linked inhibitor of apoptosis as a novel prognostic marker in radically resected non-small cell lung cancer patients. (2001) (139)
- Oral nutritional supplements containing n-3 polyunsaturated fatty acids affect quality of life and functional status in lung cancer patients during multimodality treatment: an RCT (2012) (138)
- Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. (1999) (138)
- Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials (2011) (133)
- Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome (2017) (130)
- The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs (2019) (125)
- Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review. (2000) (124)
- Integration of Gene Dosage and Gene Expression in Non-Small Cell Lung Cancer, Identification of HSP90 as Potential Target (2008) (118)
- Paclitaxel triggers cell death primarily via caspase-independent routes in the non-small cell lung cancer cell line NCI-H460. (2002) (117)
- Increased expression of the EZH2 polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis. (2004) (117)
- Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment. (2011) (112)
- Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation. (2000) (112)
- Development of [11C]erlotinib Positron Emission Tomography for In Vivo Evaluation of EGF Receptor Mutational Status (2012) (111)
- Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study. (2019) (110)
- Repeatability of Metabolically Active Volume Measurements with 18F-FDG and 18F-FLT PET in Non–Small Cell Lung Cancer (2010) (109)
- Right ventricular contractility in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension (2008) (108)
- Monitoring Response to Antiangiogenic Therapy in Non–Small Cell Lung Cancer Using Imaging Markers Derived from PET and Dynamic Contrast-Enhanced MRI (2011) (105)
- Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment? (2010) (103)
- EGFR mutated non-small cell lung cancer patients: more prone to development of bone and brain metastases? (2014) (101)
- Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in Patients (2016) (101)
- Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases. a phase II study of the EORTC Lung Cancer Group (08965). (2003) (100)
- The performance of 18F-fluorodeoxyglucose positron emission tomography in small solitary pulmonary nodules (2004) (99)
- Design of clinical trials of radiation combined with antiangiogenic therapy. (2007) (98)
- Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors (2018) (96)
- Chemotherapy for brain metastases of lung cancer: a review. (1999) (95)
- Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01. (2020) (94)
- Biodistribution and radiation dosimetry of 11C-labelled docetaxel in cancer patients (2010) (92)
- Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens. (2015) (91)
- Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry. (2010) (90)
- Molecular Tumor Boards: current practice and future needs (2017) (89)
- A phase II study of oral etoposide in elderly patients with small cell lung cancer. (1989) (87)
- A Multicenter Phase II Study of Erlotinib and Sorafenib in Chemotherapy-Naïve Patients with Advanced Non–Small Cell Lung Cancer (2010) (86)
- Does change in health-related quality of life score predict survival? Analysis of EORTC 08975 lung cancer trial (2014) (86)
- Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis. (2015) (86)
- Imatinib Mesylate in Patients with WHO B3 Thymomas and Thymic Carcinomas (2009) (86)
- An EORTC randomized phase III trial of three chemotherapy regimens in advanced non-small cell lung cancer (2001) (83)
- The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment. (2003) (83)
- Challenges in Establishing Pure Lung Cancer Organoids Limit Their Utility for Personalized Medicine. (2020) (83)
- Reproducibility of quantitative 18F-3′-deoxy-3′-fluorothymidine measurements using positron emission tomography (2009) (82)
- Prophylactic Cranial Irradiation Versus Observation in Radically Treated Stage III Non-Small-Cell Lung Cancer: A Randomized Phase III NVALT-11/DLCRG-02 Study. (2018) (81)
- Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP). (2019) (80)
- A Phase II Study of Sorafenib in Patients with Platinum-Pretreated, Advanced (Stage IIIb or IV) Non–Small Cell Lung Cancer with a KRAS Mutation (2012) (78)
- Towards a minimally invasive staging strategy in NSCLC: analysis of PET positive mediastinal lesions by EUS-FNA. (2004) (77)
- mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial (2021) (75)
- Patient reported outcomes following stereotactic ablative radiotherapy or surgery for stage IA non-small-cell lung cancer: Results from the ROSEL multicenter randomized trial. (2015) (73)
- Characteristics of Interstitial Fibrosis and Inflammatory Cell Infiltration in Right Ventricles of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (2010) (73)
- First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging. (2011) (72)
- Brigatinib in Crizotinib-Refractory ALK+ Non-Small Cell Lung Cancer: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. (2019) (71)
- Arginase-1 mRNA expression correlates with myeloid-derived suppressor cell levels in peripheral blood of NSCLC patients. (2013) (71)
- Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials. (2010) (71)
- A randomized trial of radical surgery (S) versus thoracic radiotherapy (TRT) in patients (pts) with stage IIIA-N2 non-small cell lung cancer (NSCLC) after response to induction chemotherapy (ICT) (EORTC 08941) (2005) (70)
- Early Detection of Preinvasive Lesions in High-Risk Patients: A Comparison of Conventional Flexible and Fluorescence Bronchoscopy (1998) (70)
- Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer. (2009) (69)
- Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter? (2017) (68)
- Adherence and patients’ experiences with the use of oral anticancer agents (2014) (68)
- A Panel of High Resolution Melting (HRM) Technology-Based Assays with Direct Sequencing Possibility for Effective Mutation Screening of EGFR and K-ras Genes (2009) (67)
- European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer. (2003) (67)
- Second-line chemotherapy and its evaluation in small cell lung cancer. (1999) (66)
- Single-agent gemcitabine in patients with resistant small-cell lung cancer. (2001) (66)
- Association of Polymorphisms in AKT1 and EGFR with Clinical Outcome and Toxicity in Non–Small Cell Lung Cancer Patients Treated with Gefitinib (2010) (66)
- Evaluation of NGS and RT‐PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project (2017) (66)
- Measuring response to therapy using FDG PET: semi-quantitative and full kinetic analysis (2011) (66)
- A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb–IV non-small-cell lung cancer who failed first-line treatment (2004) (66)
- How to Make the Best Use of Immunotherapy as First-Line Treatment for Advanced/Metastatic Non-Small-Cell Lung Cancer. (2019) (66)
- Toward Prediction of Efficacy of Chemotherapy: A Proof of Concept Study in Lung Cancer Patients Using [11C]docetaxel and Positron Emission Tomography (2012) (65)
- Possible role of imatinib in clinical pulmonary veno-occlusive disease (2008) (64)
- The performance of( 18)F-fluorodeoxyglucose positron emission tomography in small solitary pulmonary nodules. (2004) (64)
- Teniposide for brain metastases of small-cell lung cancer: a phase II study. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. (1995) (64)
- Practice, efficacy and cost of staging suspected non-small cell lung cancer: a retrospective study in two Dutch hospitals (2002) (64)
- Measurement of perfusion in stage IIIA-N2 non-small cell lung cancer using H(2)(15)O and positron emission tomography. (2002) (64)
- Repeatability of Quantitative Whole-Body 18F-FDG PET/CT Uptake Measures as Function of Uptake Interval and Lesion Selection in Non–Small Cell Lung Cancer Patients (2016) (64)
- Fluorescence bronchoscopy for early detection of lung cancer: a clinical perspective. (2001) (64)
- Diminished expression of multidrug resistance-associated protein 1 (MRP1) in bronchial epithelium of COPD patients (2006) (63)
- Randomized Controlled Trial of Resection Versus Radiotherapy After Induction Chemotherapy in Stage IIIA-N 2 Non – Small-Cell Lung Cancer (2007) (62)
- Expression of the p16(INK4a) gene product, methylation of the p16(INK4a) promoter region and expression of the polycomb-group gene BMI-1 in squamous cell lung carcinoma and premalignant endobronchial lesions. (2005) (62)
- Critical review of nonsurgical treatment options for stage I non-small cell lung cancer. (2008) (62)
- PHASE II ACTIVITY OF THE HSP90 INHIBITOR AUY922 IN PATIENTS WITH ALK-REARRANGED (ALK plus ) OR EGFR-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) (2012) (61)
- Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first‐line platinum‐gemcitabine chemotherapy (2012) (61)
- Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation (2014) (61)
- Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study. (2015) (59)
- Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors. (2004) (59)
- Combined sputum hypermethylation and eNose analysis for lung cancer diagnosis (2014) (59)
- Immunoglobulin-like transcript 3 is expressed by myeloid-derived suppressor cells and correlates with survival in patients with non-small cell lung cancer (2015) (59)
- Carboplatin and paclitaxol (Taxol) as an induction regimen for patients with biopsy-proven stage IIIA N2 non-small cell lung cancer. an EORTC phase II study (EORTC 08958). (2003) (58)
- Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. (2019) (58)
- Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment (2016) (57)
- KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA. (2012) (57)
- Pulmonary toxicity after bevacizumab and concurrent thoracic radiotherapy observed in a phase I study for inoperable stage III non-small-cell lung cancer. (2012) (57)
- Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic (2020) (56)
- Influenza vaccination in patients with lung cancer receiving anti-programmed death receptor 1 immunotherapy does not induce immune-related adverse events. (2018) (56)
- ACTIVITY OF AFATINIB/CETUXIMAB IN PATIENTS (PTS) WITH EGFR MUTANT NON-SMALL CELL LUNG CANCER (NSCLC) AND ACQUIRED RESISTANCE (AR) TO EGFR INHIBITORS (2012) (55)
- Stepped care targeting psychological distress in head and neck and lung cancer patients: a randomized clinical trial (2012) (54)
- BRAF mutations in non-small-cell lung cancer. (2014) (54)
- Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: A secondary analysis of the Phase III CREST trial. (2017) (53)
- Afatinib and Cetuximab in Four Patients With EGFR Exon 20 Insertion–Positive Advanced NSCLC (2018) (53)
- A phase I-II study of gemcitabine and paclitaxel in advanced non-small-cell lung cancer patients. (2000) (53)
- Reproducibility of Tumor Perfusion Measurements Using 15O-Labeled Water and PET (2008) (53)
- A Fast, Sensitive and Accurate High Resolution Melting (HRM) Technology-Based Assay to Screen for Common K-ras Mutations (2009) (52)
- Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): First report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA). (2016) (52)
- Phase II study of the HSP90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC). (2012) (52)
- Quantitative Parametric Perfusion Images Using 15O-Labeled Water and a Clinical PET/CT Scanner: Test–Retest Variability in Lung Cancer (2010) (51)
- Pre-cachexia and cachexia at diagnosis of stage III non-small-cell lung carcinoma: an exploratory study comparing two consensus-based frameworks (2012) (51)
- Acute and cumulative effects of carboplatin on renal function. (1989) (51)
- Phase 2 Study of the HSP‐90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non–Small Cell Lung Cancer (2017) (51)
- Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology (2014) (51)
- Carboplatin as second line treatment for recurrent or progressive brain metastases from small cell lung cancer. (1993) (51)
- Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: Analysis from the European FRAME study. (2015) (50)
- Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer. (2019) (50)
- Stepped care targeting psychological distress in head and neck cancer and lung cancer patients: a randomized, controlled trial. (2016) (49)
- High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases--one with a remarkable thoracic response as well. (2013) (49)
- COVID-19 vaccination: the VOICE for patients with cancer (2021) (49)
- A genome‐wide siRNA screen for regulators of tumor suppressor p53 activity in human non‐small cell lung cancer cells identifies components of the RNA splicing machinery as targets for anticancer treatment (2017) (48)
- Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial. (2012) (48)
- Treatment of multiple primary lung cancers using stereotactic radiotherapy, either with or without surgery. (2013) (47)
- Single organ metastatic disease and local disease status, prognostic factors for overall survival in stage IV non-small cell lung cancer: Results from a population-based study. (2015) (47)
- VeriStrat® has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib (2012) (47)
- Updated survival of patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D + trametinib (T) in the phase II BRF113928 study. (2017) (44)
- A Parallel Dose-Escalation Study of Weekly and Twice-Weekly Bortezomib in Combination with Gemcitabine and Cisplatin in the First-Line Treatment of Patients with Advanced Solid Tumors (2007) (44)
- Results of Two Years Expenience with Fluorescence Bronchoscopy in Detection of Preinvasive Bronchial Neoplasia (1999) (44)
- MISSION Trial - A phase III, multi-center, placebo-controlled trial of sorafenib in patients with relapsed or refractory predominantly non-squamous NSCLC after 2 or 3 previous treatment regimens. (2015) (43)
- Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METΔex14 mutated advanced non-small cell lung cancer (NSCLC). (2018) (43)
- Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients (2008) (43)
- Outcomes of concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer and significant comorbidity. (2011) (42)
- Salvage surgery for locoregional recurrence or persistent tumor after high dose chemoradiotherapy for locally advanced non-small cell lung cancer. (2016) (42)
- Prospective use of serial questionnaires to evaluate the therapeutic efficacy of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in suspected lung cancer (2003) (42)
- Pilot study of 89Zr-bevacizumab positron emission tomography in patients with advanced non-small cell lung cancer (2014) (42)
- Affordable Luciferase Reporter Assay for Cell-Based High-Throughput Screening (2013) (42)
- A phase 1B, open-label, dose-escalation study of bortezomib in combination with gemcitabine (Gem) and cisplatin (Cis) in the first-line treatment of patients with advanced solid tumors: Preliminary results of a phase IB study (2005) (41)
- A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956). (2005) (41)
- Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report. (2010) (41)
- DNA hypermethylation analysis in sputum for the diagnosis of lung cancer: training validation set approach (2015) (40)
- [Breast cancer in the early stage]. (2012) (39)
- Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin. (2012) (39)
- Development of [18F]afatinib as new TKI-PET tracer for EGFR positive tumors. (2014) (38)
- Transformation to a squamous cell carcinoma phenotype of an EGFR-mutated NSCLC patient after treatment with an EGFR-tyrosine kinase inhibitor (2015) (38)
- Molecular Pathology of Non-Small-Cell Lung Cancer (2005) (38)
- VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528. (2013) (37)
- Why Do Patients and Caregivers Seek Answers From the Internet and Online Lung Specialists? A Qualitative Study (2014) (37)
- Time and dose-related changes in radiological lung density after concurrent chemoradiotherapy for lung cancer. (2011) (37)
- Platelet-derived growth factor receptor-β and epidermal growth factor receptor in pulmonary vasculature of systemic sclerosis-associated pulmonary arterial hypertension versus idiopathic pulmonary arterial hypertension and pulmonary veno-occlusive disease: a case-control study (2011) (37)
- A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [11C]erlotinib and [18F]afatinib in lung cancer-bearing mice (2015) (37)
- Deletions of 11q22.3-q25 are associated with atypical lung carcinoids and poor clinical outcome. (2011) (36)
- Quantification of PD-L1 Expression with 18F-BMS-986192 PET/CT in Patients with Advanced-Stage Non–Small Cell Lung Cancer (2020) (36)
- The force of HER2 - A druggable target in NSCLC? (2020) (36)
- KRAS Mutations in Advanced Nonsquamous Non–Small-Cell Lung Cancer Patients Treated with First-Line Platinum-Based Chemotherapy Have No Predictive Value (2013) (36)
- A patient perspective on shared decision making in stage I non-small cell lung cancer: a mixed methods study (2015) (35)
- Genetic Heterogeneity in Patients with Multiple Neoplastic Lung Lesions: A Report of Three Cases (2007) (35)
- Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment (2018) (34)
- NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor (2015) (34)
- Observer Variability in Histopathologic Reporting of Bronchial Biopsy Specimens: Influence on the Results of Autofluorescence Bronchoscopy in Detection of Preinvasive Bronchial Neoplasia (2000) (34)
- OA04.05 Trastuzumab Deruxtecan in HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Interim Results of DESTINY-Lung01 (2021) (33)
- Adherence, exposure and patients’ experiences with the use of erlotinib in non-small cell lung cancer (2015) (33)
- Personalizing NSCLC therapy by characterizing tumors using TKI-PET and immuno-PET. (2017) (33)
- DNA copy number alterations in endobronchial squamous metaplastic lesions predict lung cancer. (2011) (33)
- Correlation of immunohistochemical staining p63 and TTF-1 with EGFR and K-ras mutational spectrum and diagnostic reproducibility in non small cell lung carcinoma (2012) (33)
- PD-L1 IHC in NSCLC with a global and methodological perspective. (2017) (32)
- New prognostic factors in resectable non-small cell lung cancer. (1996) (32)
- Differences between pulmonologists, thoracic surgeons and radiation oncologists in deciding on the treatment of stage I non-small cell lung cancer: A binary choice experiment. (2015) (31)
- Pharmacokinetics and scintigraphy of indium-111-DTPA-MOC-31 in small-cell lung carcinoma. (1995) (31)
- Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group. (2004) (31)
- A phase II study of erlotinib as first-line treatment of advanced non-small cell lung cancer. (2005) (31)
- CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients (2009) (31)
- Testing the possible non-cross resistance of two equipotent combination chemotherapy regimens against small-cell lung cancer: a phase II study of the EORTC Lung Cancer Cooperative Group. (1993) (30)
- Pharmacokinetic analysis of [18F]FAZA in non-small cell lung cancer patients (2013) (30)
- Side-Effects of Long-Term Administration of Erlotinib in Patients with Non-small Cell Lung Cancer (2010) (30)
- Restaging of Mediastinal Nodes with Transbronchial Needle Aspiration after Induction Chemoradiation for Locally Advanced Non-small Cell Lung Cancer (2007) (30)
- Lungscape: Resected Non–Small-Cell Lung Cancer Outcome by Clinical and Pathological Parameters (2014) (30)
- High-Risk Human Papillomavirus–Positive Lung Cancer: Molecular Evidence for a Pattern of Pulmonary Metastasis (2013) (30)
- Analysis of AKT and ERK1/2 protein kinases in extracellular vesicles isolated from blood of patients with cancer (2014) (29)
- Accuracy and Precision of Partial-Volume Correction in Oncological PET/CT Studies (2016) (29)
- Study of 89Zr-Pembrolizumab PET/CT in Patients With Advanced-Stage Non–Small Cell Lung Cancer (2021) (29)
- Effects of erlotinib therapy on [11C]erlotinib uptake in EGFR mutated, advanced NSCLC (2016) (29)
- Monotherapy Administration of Sorafenib in Patients with Non-Small Cell Lung Cancer: Phase III, Randomized, Double-Blind, Placebo-Controlled Mission Trial (2012) (28)
- Predictive role of repair enzymes in the efficacy of Cisplatin combinations in pancreatic and lung cancer. (2014) (28)
- A randomized, open-label, phase 2 study of emibetuzumab plus erlotinib (LY+E) and emibetuzumab monotherapy (LY) in patients with acquired resistance to erlotinib and MET diagnostic positive (MET Dx+) metastatic NSCLC. (2016) (28)
- Limited evolution of the actionable metastatic cancer genome under therapeutic pressure (2021) (28)
- EGFR mutation analysis in sputum of lung cancer patients: a multitechnique study. (2013) (28)
- Osteoblastic Bone Lesions Developing During Treatment with Erlotinib Indicate Major Response in Patients with Non-small Cell Lung Cancer: A Brief Report (2010) (28)
- Tumor Cavitation in Patients With Stage III Non–Small-Cell Lung Cancer Undergoing Concurrent Chemoradiotherapy: Incidence and Outcomes (2012) (27)
- A randomized phase II study comparing paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches in patients with stage IV nonsquamous nonsmall-cell lung cancer: NVALT12 (NCT01171170)†. (2015) (27)
- LBA38_PRDABRAFENIB IN PATIENTS WITH BRAF V600E-MUTANT ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A MULTICENTER, OPEN-LABEL, PHASE II TRIAL (BRF113928) (2014) (27)
- Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer. (2012) (27)
- Fatal interstitial lung disease after erlotinib for non-small cell lung cancer. (2008) (27)
- Treatment guidance for lung cancer patients during the COVID-19 pandemic (2020) (27)
- DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile. (2019) (27)
- A phase II study of high dose epirubicin in unresectable non small cell lung cancer. (1992) (27)
- Tumor flare after start of RAF inhibition in KRAS mutated NSCLC: a case report. (2015) (26)
- A single-arm phase II trial of afatinib in pretreated patients with advanced NSCLC harboring a HER2 mutation: The ETOP NICHE trial. (2017) (26)
- Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin. (2012) (26)
- A phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma. (2002) (26)
- PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non–Small Cell Lung Cancer (2021) (26)
- Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays’ and cross-validation with resections, in patients with, stage I–III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort (2019) (26)
- Second primary lung cancers following a diagnosis of primary head and neck cancer. (2015) (26)
- Retrospective evaluation of thromboembolic events in patients with non-small cell lung cancer treated with platinum-based chemotherapy. (2014) (26)
- Mechanisms for high methoxymorpholino doxorubicin cytotoxicity in doxorubicin‐resistant tumor cell lines (1997) (26)
- Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancer. (2015) (26)
- Treatment of relapsed small cell lung cancer. (2001) (26)
- Elevated hTERT mRNA levels: A potential determinant of bronchial squamous cell carcinoma (in situ) (2004) (25)
- Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications (2017) (25)
- MEK114653: A randomized, multicenter, phase II study to assess efficacy and safety of trametinib (T) compared with docetaxel (D) in KRAS-mutant advanced non-small cell lung cancer (NSCLC). (2013) (25)
- Cost-Utility of Stepped Care Targeting Psychological Distress in Patients With Head and Neck or Lung Cancer. (2017) (25)
- Quantitative and Simplified Analysis of 11C-Erlotinib Studies (2016) (25)
- Repeatability of [18F]FDG PET/CT total metabolic active tumour volume and total tumour burden in NSCLC patients (2019) (25)
- Negative NKX2-1 (TTF-1) as Temporary Surrogate Marker for Treatment Selection During EGFR-Mutation Analysis in Patients with Non–Small-Cell Lung Cancer (2012) (24)
- Population‐Based Patterns of Surgical Care for Stage IIIA NSCLC in the Netherlands between 2010 and 2013 (2016) (24)
- Surgical resection for small cell carcinoma of the lung: a retrospective study. (1994) (24)
- Close Surveillance with Long-Term Follow-up of Subjects with Preinvasive Endobronchial Lesions. (2015) (24)
- Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC). (2019) (24)
- Induction of Peripheral Effector CD8 T-cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Non–small Cell Lung Cancer Patients (2019) (24)
- Membrane diffusion- and capillary blood volume measurements are not useful as screening tools for pulmonary arterial hypertension in systemic sclerosis: a case control study (2008) (23)
- Pemetrexed Induced Thymidylate Synthase Inhibition in Non-Small Cell Lung Cancer Patients: A Pilot Study with 3′-Deoxy-3′-[18F]fluorothymidine Positron Emission Tomography (2013) (23)
- The efficacy of Life Review Therapy combined with Memory Specificity Training (LRT-MST) targeting cancer patients in palliative care: A randomized controlled trial (2018) (23)
- Metabolic activity measured by FDG PET predicts pathological response in locally advanced superior sulcus NSCLC. (2014) (23)
- Decreased phenytoin level after carboplatin treatment. (1990) (23)
- Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non–Small Cell Lung Cancer Failing First‐Line Platinum‐Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS‐lung Trial (2017) (23)
- CT detected indeterminate pulmonary nodules in a chemoprevention trial of fluticasone. (2008) (23)
- Peptide-mediated ‘miniprep’ isolation of extracellular vesicles is suitable for high-throughput proteomics (2016) (23)
- Trimodality therapy for superior sulcus tumours: evolution and evaluation of a treatment protocol. (2013) (22)
- Cell-free DNA in the supernatant of pleural effusion can be used to detect driver and resistance mutations, and can guide tyrosine kinase inhibitor treatment decisions (2019) (22)
- Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cells. (2013) (22)
- Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice (2021) (22)
- Tc-99m-Sestamibi scanning with SDZ PSC 833 as a functional detection method for resistance modulation in patients with solid tumours (1999) (22)
- Phase III study of cyclophosphamide, doxorubicin, and etoposide compared with carboplatin and paclitaxel in patients with extensive disease small-cell lung cancer. (2007) (22)
- High PD-1 expression on regulatory and effector T-cells in lung cancer draining lymph nodes (2017) (21)
- Dramatic response to low-dose erlotinib of epidermal growth factor receptor mutation-positive recurrent non-small cell lung cancer after severe cutaneous toxicity. (2009) (21)
- Bronchial Intraepithelial Neoplastic Lesions in Head and Neck Cancer Patients: Results of Autofluorescence Bronchoscopy (2001) (21)
- Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy (2020) (21)
- The use of erlotinib in daily practice: a study on adherence and patients' experiences (2011) (21)
- Costs of non-small cell lung cancer in the Netherlands. (2016) (21)
- 18 fluoro-2-deoxyglucose positron emission tomography (PET) in the assessment of induction chemotherapy in stage IIIA-N2 NSCLC: a multi-center prospective study (2001) (21)
- [18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches (2016) (21)
- Assessment of Simplified Methods to Measure 18F-FLT Uptake Changes in EGFR-Mutated Non–Small Cell Lung Cancer Patients Undergoing EGFR Tyrosine Kinase Inhibitor Treatment (2014) (21)
- Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer (2019) (20)
- A phase II study of erlotinib (E) and bevacizumab (B) in patients (pts) with previously untreated stage IIIB/IV non-small cell lung cancer (NSCLC) (2007) (20)
- DNA hypermethylation analysis in sputum of asymptomatic subjects at risk for lung cancer participating in the NELSON trial: argument for maximum screening interval of 2 years (2016) (20)
- Stereotactic radiotherapy for centrally located early-stage lung tumors. (2007) (20)
- EUELC project: a multi-centre, multipurpose study to investigate early stage NSCLC, and to establish a biobank for ongoing collaboration (2009) (20)
- Influence of histology and biomarkers on first-line treatment of advanced non-small cell lung cancer in routine care setting: baseline results of an observational study (FRAME). (2012) (20)
- Rearranged EML 4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer (2016) (20)
- Absolute Quantification of [11C]docetaxel Kinetics in Lung Cancer Patients Using Positron Emission Tomography (2011) (20)
- Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry. (2019) (19)
- Safety and activity of CLN-081 (TAS6417) in NSCLC with EGFR Exon 20 insertion mutations (Ins20). (2021) (19)
- Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a 'chemosensitive' relapse: A single-arm phase II study (EORTC-08061). (2016) (19)
- SUVmax during 18FDG-PET scanning in small cell lung cancer: similar information as in non-small cell lung cancer? (2012) (19)
- Time for reappraisal of extracranial treatment options? (2011) (19)
- Positron Emission Tomography as a Method for Measuring Drug Delivery to Tumors in vivo: The Example of [11C]docetaxel (2013) (19)
- Toward less futile surgery in non-small cell lung cancer? A randomized clinical trial to evaluate the cost-effectiveness of positron emission tomography. (2001) (19)
- Reproducibility of quantitative 18 F-3 ′-deoxy-3 ′-fluorothymidine measurements using positron emission tomography (2009) (18)
- Phase II trial of mta (LY231514) in patients (PTS) with non-small cell lung cancer (NSCLC) who relapsed after previous platinum or non-platinum chemotherapy (1999) (18)
- Exposure–Response Analyses of Anaplastic Lymphoma Kinase Inhibitors Crizotinib and Alectinib in Non‐Small Cell Lung Cancer Patients (2020) (18)
- The prognostic value of early onset, CT derived loss of muscle and adipose tissue during chemotherapy in metastatic non-small cell lung cancer. (2019) (18)
- Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer (2018) (18)
- The influence of fluticasone inhalation on markers of carcinogenesis in bronchial epithelium. (2007) (18)
- Variability and Repeatability of Quantitative Uptake Metrics in 18F-FDG PET/CT of Non–Small Cell Lung Cancer: Impact of Segmentation Method, Uptake Interval, and Reconstruction Protocol (2018) (18)
- Capmatinib in patients with high-level MET-amplified advanced non–small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study. (2020) (18)
- Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK+ non–small cell lung cancer (NSCLC): Efficacy updates and exploratory analysis of CNS ORR and overall ORR by baseline (BL) brain lesion status. (2018) (17)
- In vitro response of human small‐cell lung‐cancer cell lines to chemotherapeutic drugs; no correlation with clinical data (1992) (17)
- Prognostic Value of Deep Learning-Mediated Treatment Monitoring in Lung Cancer Patients Receiving Immunotherapy (2021) (17)
- Nutrition During Trimodality Treatment in Stage III Non-small Cell Lung Cancer: Not Only Important for Underweight Patients (2011) (17)
- Prolonged sampling of spontaneous sputum improves sensitivity of hypermethylation analysis for lung cancer (2012) (17)
- Parametric Methods for Quantification of 18F-FAZA Kinetics in Non–Small Cell Lung Cancer Patients (2014) (17)
- ZD1839 (‘Iressa’), an orally-active, selective, epidermal growth factor receptor tyrosine kinase inhibitor (egfr-tki), is well tolerated in combination with gemcitabine and cisplatin, in patients with advanced solid tumours: preliminary tolerability, efficacy and pharmacokinetic results (2001) (17)
- Molecular Mechanisms and Modulation of Key Pathways Underlying the Synergistic Interaction of Sorafenib with Erlotinib in Non-Small-Cell-Lung Cancer (NSCLC) Cells (2012) (17)
- Salvage surgery for local failures after stereotactic ablative radiotherapy for early stage non-small cell lung cancer (2016) (17)
- Concurrent chemoradiotherapy for large-volume locally-advanced non-small cell lung cancer. (2013) (17)
- Long-term expanding human airway organoids for disease modelling (2018) (17)
- Navigating Diagnostic and Treatment Decisions in Non‐Small Cell Lung Cancer: Expert Commentary on the Multidisciplinary Team Approach (2020) (16)
- STAGING OF NON–SMALL-CELL LUNG CANCER AND APPLICATION OF FDG-PET (2002) (16)
- Cost Effectiveness of Treatment With New Agents in Advanced Non-Small-Cell Lung Cancer: A Systematic Review (2011) (16)
- Economic evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancer (2012) (16)
- Results of whole brain radiotherapy for brain metastases of small cell lung cancer (1993) (16)
- Pemetrexed and cisplatin with concurrent radiotherapy for locally advanced non-small cell and limited disease small cell lung cancer: results from 2 phase I studies. (2010) (16)
- Pharmacology of the paclitaxel–cisplatin, gemcitabine–cisplatin, and paclitaxel–gemcitabine combinations in patients with advanced non-small cell lung cancer (2006) (16)
- Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies (2022) (16)
- Tumour growth rate as a tool for response evaluation during PD-1 treatment for non-small cell lung cancer: a retrospective analysis (2019) (16)
- Effects of gemcitabine on renal function in patients with non-small cell lung cancer. (1998) (15)
- Second-line therapy for NSCLC in clinical practice: baseline results of the European SELECTTION observational study (2010) (15)
- Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies. (2021) (15)
- Complete pathological response is predictive for clinical outcome after tri-modality therapy for carcinomas of the superior pulmonary sulcus (2013) (15)
- Effects of chemotherapy on the parotid and submandibular glands in head and neck cancer patients treated with chemoradiotherapy (2014) (15)
- Exposure–response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer (2018) (15)
- Decreased glutathione biosynthesis contributes to EGFR T790M-driven erlotinib resistance in non-small cell lung cancer (2016) (15)
- Pembrolizumab for all PD-L1-positive NSCLC (2019) (15)
- Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy (2001) (15)
- Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC). (2018) (14)
- Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib. (2017) (14)
- Second-line carboplatin-based chemotherapy for small cell lung cancer: the Groningen experience. (1992) (14)
- Treatment of brain metastases of small cell lung cancer with teniposide. (1992) (14)
- Phase Ib study of recombinant human (rh)Apo2L/TRAIL in combination with paclitaxel, carboplatin, and bevacizumab (PCB) in patients (pts) with advanced non-small cell lung cancer (NSCLC) (2008) (14)
- Cisplatin and carboplatin-based chemotherapy in the first-line treatment of non-small cell lung cancer: Analysis from the European FRAME study. (2016) (14)
- Effect of completion-time windows in the analysis of health-related quality of life outcomes in cancer patients. (2013) (14)
- A dose and schedule finding study of gemcitabine and etoposide in patients with progressive non-small cell lung cancer after platinum containing chemotherapy. (1999) (14)
- Molecular and Immune Biomarker Testing in Squamous‐Cell Lung Cancer: Effect of Current and Future Therapies and Technologies (2018) (14)
- Thoracic actinomycosis imaging with fluorine-18 fluorodeoxyglucose positron emission tomography. (1999) (13)
- Combination of gemcitabine and cisplatin for advanced non-small cell lung cancer: a phase II study with emphasis on scheduling. (2001) (13)
- Evaluation of new drugs in small cell lung cancer: the activity of gemcitabine. (1998) (13)
- Changes in non-surgical management of stage III non-small cell lung cancer at a single institution between 2003 and 2010 (2014) (13)
- Whole genome RNAi screens reveal a critical role of REV3 in coping with replication stress (2014) (13)
- Comparison of 2 analytical methods of DCE-MRI in advanced NSCLC patients treated with erlotinib and bevacizumab (2009) (13)
- Preliminary Phase II results of a multicenter, open-label study of nazartinib (EGF816) in adult patients with treatment-naïve EGFR-mutant non-small cell lung cancer (NSCLC). (2018) (13)
- Re: Autofluorescence bronchoscopy in the detection of squamous metaplasia and dysplasia in current and former smokers. (1999) (13)
- A Population‐Based Analysis of Application of WHO Nomenclature in Pathology Reports of Pulmonary Neuroendocrine Tumors (2016) (13)
- 99mTc-Sestamibi scanning with SDZ PSC 833 as a functional detection method for resistance modulation in patients with solid tumours. (1999) (13)
- A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS). (2016) (13)
- Functional Genomic Screen in Mesothelioma Reveals that Loss of Function of BRCA1-Associated Protein 1 Induces Chemoresistance to Ribonucleotide Reductase Inhibition (2019) (13)
- Second-line erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): Results from a large, open-label study (2008) (13)
- Cost Effectiveness of Treatment with New Agents in Advanced Non-Small-Cell Lung Cancer (2012) (13)
- Proteome analysis of non-small cell lung cancer cell line secretomes and patient sputum reveals biofluid biomarker candidates for cisplatin response prediction. (2019) (12)
- Treatment Patterns and Differences in Survival of Non-Small Cell Lung Cancer Patients Between Academic and Non-Academic Hospitals in the Netherlands. (2017) (12)
- Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer (Science Translational Medicine (2012) 4, (130er2)) (2011) (12)
- Surgery versus SABR for resectable non-small-cell lung cancer - Authors' reply. (2015) (12)
- P3.02a-013 Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial: Topic: ALK Clinical (2017) (12)
- Randomised phase 3 study of adjuvant chemotherapy with or without nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 study (2019) (12)
- Trimodality therapy for stage IIIA non-small cell lung cancer: benchmarking multi-disciplinary team decision-making and function. (2014) (12)
- High-throughput RNAi screening reveals cancer-selective lethal targets in the RNA spliceosome (2019) (12)
- DNA copy number aberrations in endobronchial lesions: a validated predictor for cancer (2013) (12)
- Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours (2022) (12)
- Phase (Ph) 1/2a study of CLN-081 in patients (pts) with NSCLC with EGFR exon 20 insertion mutations (Ins20). (2022) (12)
- Partial-volume correction in dynamic PET-CT: effect on tumor kinetic parameter estimation and validation of simplified metrics (2019) (11)
- Quality assessment of positron emission tomography scans: recommendations for future multicentre trials (2017) (11)
- A Serum Protein Classifier Identifying Patients with Advanced Non–Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint Inhibitors (2020) (11)
- Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses. (2018) (11)
- Suprabasal p53 immunostaining in premalignant endobronchial lesions in combination with histology is associated with bronchial cancer. (2003) (11)
- Prognostic value of hTERT mRNA expression in surgical samples of lung cancer patients: the European Early Lung Cancer Project. (2010) (11)
- Rationale and study design of the IRENE-trial (NVALT-16): a phase II trial to evaluate iressa rechallenge in advanced NSCLC patients with an activating EGFR mutation who responded to an EGFR-TKI used as first-line or previous treatment. (2015) (11)
- Interim results of a phase II single arm trial combining afatinib with cetuximab in patients with EGFRex20ins positive NSCLC. (2021) (10)
- Surgical Treatment of Complications After High-Dose Chemoradiotherapy for Lung Cancer. (2017) (10)
- Methodological Considerations in Quantification of 3'-Deoxy-3'-[18F]Fluorothymidine Uptake Measured with Positron Emission Tomography in Patients with Non-Small Cell Lung Cancer (2014) (10)
- PD-L1 in non-small-cell lung cancer: the third target for immunotherapy (2016) (10)
- Platelet- derived growth factor receptor-beta and epidermal growth factor receptor in pulmonary vasculature of systemic sclerosis-associated pulmonary arterial hypertension versus idiopathic pulmonary arterial hypertension and pulmonary veno-occlusive disease: a case-control study (2011) (10)
- High-dose, weekly erlotinib is not an effective treatment in EGFR-mutated non-small cell lung cancer-patients with acquired extracranial progressive disease on standard dose erlotinib. (2014) (10)
- Phase I study of high-dose epirubicin and vinorelbine in previously untreated non-small-cell lung cancer stage IIIB-IV. (1995) (10)
- International Experts Panel Meeting of the Italian Association of Thoracic Oncology on Antiangiogenetic Drugs for Non–Small Cell Lung Cancer: Realities and Hopes (2016) (10)
- Radiomic biomarkers for the prediction of immunotherapy outcome in patients with metastatic non-small cell lung cancer. (2017) (10)
- Sequencing chemotherapy, radiotherapy and surgery in combined modality treatment of stage III nonsmall cell lung cancer (2007) (10)
- Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment (2022) (10)
- Quality assurance of thoracic radiotherapy in EORTC 08941: a randomised trial of surgery versus thoracic radiotherapy in patients with stage IIIA non-small-cell lung cancer (NSCLC) after response to induction chemotherapy. (2006) (9)
- Whole body PD-1 and PD-L1 PET with Zr-89-nivolumab and F-18-BMS-986192 in pts with NSCLC. (2017) (9)
- Increased Expression of the EZH 2 Polycomb Group Gene in BMI-1 – Positive Neoplastic Cells during Bronchial Carcinogenesis 1 (2004) (9)
- Phase II study of high-dose epirubicin and etoposide in advanced non-small cell lung cancer. (1992) (9)
- A phase II study of erlotinib and sorafenib in chemotherapy-naive patients with locally advanced/metastatic non-small cell lung cancer (NSCLC). (2009) (9)
- Real-world utilization of biomarker testing for patients with advanced non-small-cell lung cancer in a tertiary referral center and referring hospitals. (2021) (9)
- Scheduling of anticancer drugs (2012) (9)
- 2nd ESMO Consensus Conference on Lung Cancer : non-small-cell lung cancer first-line/second and further lines in advanced disease (2014) (9)
- Silencing Core Spliceosome Sm Gene Expression Induces a Cytotoxic Splicing Switch in the Proteasome Subunit Beta 3 mRNA in Non-Small Cell Lung Cancer Cells (2020) (9)
- Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial. (2022) (8)
- Response Prediction and Evaluation Using PET in Patients with Solid Tumors Treated with Immunotherapy (2021) (8)
- Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non–small-cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study. (2020) (8)
- Low molecular weight heparins in the treatment of lung cancer (2011) (8)
- Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study (2020) (8)
- Lung Cancer Patients Benefit from Second Opinions by Improvement of Diagnosis and Therapy (2014) (8)
- A randomized phase II study of pemetrexed (P) versus pemetrexed-carboplatin (PC) as second line treatment for patients (pts) with advanced non-small-cell lung cancer (NSCLC)- NVALT 7 (2008) (8)
- Second-line therapy for non-small cell lung cancer in clinical practice: final results and treatment pathways from the SELECTTION observational study (2012) (8)
- CT-perfusion versus [(15)O]H2O PET in lung tumors: effects of CT-perfusion methodology. (2013) (8)
- Genetic subtypes of large cell neuroendocrine carcinoma (LCNEC) to predict response to chemotherapy. (2017) (8)
- CMET-22. CAPMATINIB (INC280) IN METΔEX14-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): EFFICACY DATA FROM THE PHASE 2 GEOMETRY MONO-1 STUDY (2019) (8)
- Weekly chemoradiation (docetaxel/cisplatin) followed by surgery in stage III NSCLC; a multicentre phase II study. (2010) (8)
- Iris metastasis in small-cell lung carcinoma. (2007) (8)
- Evaluation of a treatment strategy for optimising preoperative chemoradiotherapy in stage III non-small-cell lung cancer. (2009) (8)
- Does downstaging in patients (pts) with IIIA-N2 non-small cell lung cancer (NSCLC) and a response to induction chemotherapy (ICT) influence outcome with surgery (S) or radiotherapy (RT)? An exploratory analysis of EORTC 08941. (2006) (8)
- Clonality analysis of pulmonary tumors by genome-wide copy number profiling (2019) (8)
- Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review. (2022) (8)
- Patterns of care and outcomes for stage IIIB non-small cell lung cancer in the TNM-7 era: Results from the Netherlands Cancer Registry. (2017) (8)
- Clinically Relevant Information Obtained by Performing Autofluorescence Bronchoscopy (2000) (8)
- Identifying advanced stage NSCLC patients who benefit from afatinib therapy using 18F-afatinib PET/CT imaging. (2021) (8)
- Detection and localization of early- and late-stage cancers using platelet RNA. (2022) (8)
- Lung cancer in 2015: Bypassing checkpoints, overcoming resistance, and honing in on new targets (2016) (8)
- MA25.02 Searching for a Definition of Synchronous Oligometastatic (sOMD)-NSCLC: A Consensus from Thoracic Oncology Experts (2018) (8)
- Small cell lung cancer in the elderly. Factors influencing the results of chemotherapy: a review (1989) (8)
- Health-related quality of life after prophylactic cranial irradiation for stage III non-small cell lung cancer patients: Results from the NVALT-11/DLCRG-02 phase III study. (2019) (8)
- Quantification of [18F]afatinib using PET/CT in NSCLC patients: a feasibility study (2020) (8)
- Randomized phase III study of adjuvant chemotherapy with or without low-molecular weight heparin in completely resected non-small cell lung cancer patients: The NVALT-8 study. (2016) (7)
- Comprehensive CADM1 promoter methylation analysis in NSCLC and normal lung specimens. (2011) (7)
- Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance (2020) (7)
- Trastuzumab and paclitaxel in patients (pts) with EGFR mutated non-small-cell lung cancer (NSCLC) that express HER2 after progression on EGFR TKI treatment. (2017) (7)
- Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage III1 N2 non-small-cell lung cancer: a phase II study of the european organization for research and treatment of cancer (2000) (7)
- Measurement of tumor and myocardial perfusion using 15O-water and a clinical PET-CT scanner (2009) (7)
- Stages I-II non-small cell lung cancer treated using either lobectomy by video-assisted thoracoscopic surgery (VATS) or stereotactic ablative radiotherapy (SABR): Outcomes of a propensity score-matched analysis. (2012) (7)
- OA01.07 Capmatinib (INC280) in METΔEX14-Mutated Advanced NSCLC: Efficacy Data from the Phase 2 Geometry MONO-1 Study (2019) (7)
- P2.13-42 Osimertinib Treatment for Patients with EGFR exon 20 Insertion Positive Non-Small-Cell Lung Cancer (2018) (7)
- Randomized multicenter phase II study of chemotherapy followed by surgery versus surgery alone in stage I and II non-small cell lung cancer (NSCLC) (2000) (7)
- ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib. (2019) (7)
- Is the current diagnostic algorithm reliable for selecting cases for EGFR- and KRAS-mutation analysis in lung cancer? (2015) (7)
- Treatment of central nervous system metastases from small cell lung cancer with chemotherapy (1993) (7)
- A phase I study of sequential intravenous topotecan and etoposide in lung cancer patients. (2001) (7)
- Exposure-response relationship for ramucirumab (RAM) from the randomized, double-blind, phase III REVEL trial (docetaxel [DOC] vs DOC plus RAM) in second-line treatment of metastatic non-small cell lung cancer (NSCLC). (2015) (7)
- Osimertinib treatment for patients with EGFR exon 20 insertion positive non-small cell lung cancer. (2018) (7)
- Stepped care targeting psychological distress in head and neck cancer and lung cancer patients: which groups specifically benefit? Secondary analyses of a randomized controlled trial (2019) (7)
- FDG-PET in addition to conventional work-up in non-small-cell lung cancer. (2005) (7)
- Abstract CT167: Pooled analysis of drug-related interstitial lung disease (ILD) in 8 single-arm trastuzumab deruxtecan (T-DXd) studies (2021) (6)
- Imaging Responses to Immunotherapy with Novel PET Tracers (2020) (6)
- Stereotactic Ablative Radiotherapy (SABR) in Potentially Operable Patients with Stage I Non-small Cell Lung Cancer (2011) (6)
- Stereotactic Ablative Radiotherapy Induces Peripheral T-Cell Activation in Patients with Early-Stage Lung Cancer. (2017) (6)
- Endoscopic ultrasound guided fine-needle aspiration and 18FDG-positron emission tomography in the evaluation of patients with non-small cell lung cancer. (2007) (6)
- MA11.03 Trastuzumab Deruxtecan in HER2-Mutated Metastatic Non-Small Cell Lung Cancer (NSCLC): Interim Results of DESTINY-Lung01 (2021) (6)
- PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC (2022) (6)
- Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy (2016) (6)
- Effects of the antiangiogenic drug bevacizumab on tumor perfusion and drug delivery of 11C-labeled docetaxel in patients with non-small cell lung cancer (NSCLC): Implications for scheduling of antiangiogenic agents. (2011) (6)
- Phase II study of imatinib in patients with WHO B3 and C thymomas (2008) (6)
- Platelet-derived growth factor receptor-b and epidermal growth factor receptor in pulmonary vasculature of systemic sclerosis-associated pulmonary arterial hypertension versus idiopathic pulmonary arterial hypertension and pulmonary veno-occlusive disease: a case-control study (2011) (6)
- Intracranial activity of tepotinib in patients (pts) with MET exon 14 (METex14) skipping NSCLC enrolled in VISION. (2021) (6)
- MA11.05 Tepotinib in Patients with MET exon 14 (METex14) Skipping Advanced NSCLC: Updated Efficacy Results from VISION Cohort A (2021) (6)
- Efficacy of crizotinib in ROS1-rearranged lung cancer: The European experience. (2014) (6)
- Updated analysis of the efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumors. (2022) (6)
- Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): Updates from ALTA, a pivotal randomized phase 2 trial. (2017) (6)
- Abstract CT082: Capmatinib inMETex14-mutated (mut) advanced non-small cell lung cancer (NSCLC): Results from the phase II GEOMETRYmono-1study, including efficacy in patients (pts) with brain metastases (BM) (2020) (6)
- Lung Cancer in the Netherlands. (2021) (6)
- Challenges in the Management of EGFR-Mutated Non-Small Cell Lung Cancer Patients with Acquired Resistance to Tyrosine Kinase Inhibitors (2014) (5)
- Phase II results for single-agent nazartinib (EGF816) in adult patients (pts) with treatment-naive EGFR-mutant non-small cell lung cancer (NSCLC). (2018) (5)
- Dose-finding and pharmacological study of ifosfamide in combination with paclitaxel and carboplatin in resistant small-cell lung cancer. (2001) (5)
- Small-cell lung cancer: is there a standard therapy? (1998) (5)
- O-4 A randomized phase II study of docetaxel versus docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first line chemotherapy (2003) (5)
- A randomized phase II study of paclitaxel-carboplatin-bevacizumab (PCB) with or without nitroglycerin patches (NTG) in patients (pts) with stage IV nonsquamous non-small cell lung cancer (NSCLC): Nvalt 12 (NCT01171170). (2014) (5)
- Efficacy and safety results from CurrentS, a double-blind, randomized, phase III study of second-line erlotinib (150 mg versus 300 mg) in current smokers with advanced non-small cell lung cancer (NSCLC). (2014) (5)
- Response and toxicity prediction by MALDI‐TOF‐MS serum peptide profiling in patients with non‐small cell lung cancer (2016) (5)
- Why we should improve current practice of diagnosing and treating pulmonary large cell neuroendocrine carcinomas in patients with advanced disease (2017) (5)
- Clinical recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer, small-cell lung cancer and malignant pleural mesothelioma (2007) (5)
- PCN93 Cost-Effectiveness of Treatment with New Agents in Advanced Non-Small-Cell Lung Cancer: A Systematic Review (2011) (5)
- Semiautomated volumetric response evaluation as an imaging biomarker in superior sulcus tumors (2014) (5)
- First-in-human study of 89 Zr-pembrolizumab PET/CT in patients with advanced stage non-small-cell lung cancer (2021) (5)
- Harmonising patient-access programmes: the Dutch DRUG Access Protocol platform. (2022) (5)
- Reduction in thyroid perfusion after bevacizumab treatment. (2013) (5)
- Towards prediction of efficacy of chemotherapy: a proof of concept study in lung cancer patients using [ 11 C]docetaxel and positron emission tomography (2013) (5)
- Pan-cancer whole-genome analyses of metastatic solid tumours (2019) (5)
- Validation of [18F]FLT as a perfusion-independent imaging biomarker of tumour response in EGFR-mutated NSCLC patients undergoing treatment with an EGFR tyrosine kinase inhibitor (2018) (4)
- Is the routine use of trimodality therapy for selected patients with non-small cell lung cancer supported by long-term clinical outcomes? (2017) (4)
- Sorafenib and metformin in pretreated patients with stage IV non-small cell lung cancer with a KRAS mutation: A multicenter single arm phase II study. (2014) (4)
- Genome-wide silencing screen in mesothelioma cells reveals that loss of function of BAP1 induces chemoresistance to ribonucleotide reductase inhibition: implication for therapy (2018) (4)
- Parametric Method Performance for Dynamic 3′-Deoxy-3′-18F-Fluorothymidine PET/CT in Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Carcinoma Patients Before and During Therapy (2017) (4)
- Cancer therapy: could a novel test predict the amount of drug that reaches its target? (2013) (4)
- 98O_PRTARGETED THERAPY FOR BRAF-MUTANT LUNG CANCER: RESULTS FROM THE EUROPEAN EURAF COHORT STUDY (2015) (4)
- Prophylactic cranial irradiation (PCI) versus observation in radically treated stage III non-small cell lung cancer (NSCLC): A randomized phase III NVALT11 study. (2017) (4)
- A Phase II Study of Sorafenlb In Patients with Locally Advanced And/or Metastatic (stage 1MB or IV) Non-small Cell Lung Cancer (NSCLC) with a K-Ras Mutation (2011) (4)
- Nazartinib (EGF816) in patients with treatment-naïve EGFR-mutant non-small cell lung cancer (NSCLC): Updated phase II results. (2020) (4)
- Rebiopsy in TKI-resistance: A retrospective analysis. (2013) (4)
- The Finding of Premalignant Lesions is Not Associated with Smoking Cessation in Chemoprevention Study Volunteers (2010) (4)
- B11 Accurate Detection of METex14 Mutations in Non-Small Cell Lung Cancer (NSCLC) with Comprehensive Genomic Sequencing: Results from the GEOMETRY Mono-1 Study (2020) (4)
- A phase II study of first-line erlotinib in patients (pts) with stage IIIB/IV non-small-cell lung cancer (NSCLC) including dose escalation to toxicity in current and former smokers (C/FS) (2008) (4)
- Bevacizumab in neoadjuvant treatment for breast cancer. (2012) (4)
- Real-world insights into patients with advanced NSCLC and MET alterations (2021) (4)
- Review: Angiogenesis inhibitors in the treatment of non-small cell lung cancer (2009) (4)
- Efficacy and safety of patritumab deruxtecan (HER3-DXd) in advanced/metastatic non-small cell lung cancer (NSCLC) without EGFR-activating mutations. (2022) (4)
- MTA (LY231514): a phase II trial in patients (PTS) with non-small cell lung cancer (NSCLC) who relapsed after previous platinum or non-platinum chemotherapy (1999) (4)
- P1.04-12 Tumor Uptake and Biodistribution of 89Zr-Labeled Pembrolizumab in Patients with Metastatic Non-Small-Cell Lung Cancer (2019) (3)
- EML4-ALK rearrangement in blood platelets and outcome to crizotinib in non-small-cell lung cancer patients. (2015) (3)
- Complications of endoscopic ultrasound-guided needle aspiration (2014) (3)
- Inter-reader reproducibility of dynamic contrast-enhanced magnetic resonance imaging in patients with non-small cell lung cancer treated with bevacizumab and erlotinib. (2016) (3)
- Phase III study comparing cyclophosphamide, doxorubicin, and etoposide (CDE) to carboplatin and paclitaxel (CP) in patients (pts) with extensive disease small cell lung cancer (ED SCLC). (2005) (3)
- Tobacco smoking related mutational signatures in classifying smoking associated and non-smoking associated non-small cell lung cancer. (2022) (3)
- P-485 EGFR mutations do not accurately predict response to erlotinib in first-line monotherapy treatment of advanced non-small-cell lung cancer (2005) (3)
- Identifying Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Most Likely to Benefit From Intensive Radiation Therapy (2016) (3)
- Continued Afatinib (A) With the Addition of Cetuximab (C) After Progression on Afatinib in Patients With Acquired Resistance (AR) to Gefitinib (G) or Erlotinib (E) (2014) (3)
- Randomized controlled trial (RCT) to evaluate the cost-effectiveness of positron emission tomography (PET) added to conventional diagnostic strategies in non-small cell lung cancer (NSCLC) (2000) (3)
- A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib. (2022) (3)
- Outcome After Stereotactic Radiotherapy in ‘High-Risk’ Patients With Stage I Non-small Cell Lung Cancer (NSCLC) (2007) (3)
- A Randomized Phase II Study Comparing Erlotinib (E) Versus e Alternating with Chemotherapy in Relapsed Non-Small Cell Lung Cancer (NSCLC) Patients. The NVALT10 Study (2012) (3)
- [New therapies for the treatment of advanced non-small cell lung cancer: inhibitors of the epidermal growth factor receptor and angiogenesis]. (2008) (3)
- [Bacteremia caused by Streptococcus salivarius and S. Milleri, and colonic carcinoma]. (1994) (3)
- Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer. (2022) (3)
- MA02.07 T-DM1 and Osimertinib (TRAEMOS) To Target HER2 Bypass Track Resistance in EGFRm+ NSCLC: Interim Analysis of a Phase II Trial (2021) (3)
- Sorafenib in pretreated patients with advanced non-small lung cancer harbouring a K-ras mutation (2009) (3)
- The implementation of PET in non-small-cell lung cancer in the Netherlands. (2006) (3)
- 1254P Efficacy and safety of tepotinib in patients (pts) with advanced age: VISION subgroup analysis of pts with MET exon 14 (METex14) skipping NSCLC (2021) (3)
- Carboplatin and renal function. (1989) (3)
- Abstract 4956: CD34bright/CD133negcandidate circulating endothelial progenitor cells (ccEPCs) are a potential biomarker during treatment with sunitinib or bevacizumab (2008) (3)
- Molecular Cancer Therapeutics Association of Polymorphisms in AKT 1 and EGFR with Clinical Outcome and Toxicity in Non – Small Cell Lung Cancer Patients Treated with Gefitinib (2010) (3)
- Oral therapy for small cell lung cancer. (1995) (3)
- A phase II study of weekly docetaxel/cisplatin and concurrent radiotherapy followed by surgery in patients with stage III non-small cell lung cancer (NSCLC) (2007) (3)
- Pemetrexed pathway-associated germline polymorphisms: a useful tool for treatment individualization? (2010) (3)
- Phase II two-arm study of tepotinib plus osimertinib in patients with EGFR-mutant NSCLC and acquired resistance to first-line osimertinib due to MET amplification: INSIGHT 2. (2021) (3)
- 251 A randomized phase II trial of neoadjuvant chemotherapy followed by surgery versus surgery alone in patients with stage I, II and IIIA (N0) non-small cell lung cancer. Preliminary analysis (1997) (3)
- Prophylactic cranial irradiation for stage IV small cell lung cancer, live longer or reduce morbidity of brain metastases? (2017) (3)
- Optimized Dosing: The Next Step in Precision Medicine in Non-Small-Cell Lung Cancer (2021) (3)
- Exposure-response analyses of ALK-inhibitors crizotinib and alectinib in NSCLC patients (2019) (3)
- Phase II study of danusertib (D) in advanced/metastatic non-small cell lung cancers (NSCLC). (2013) (3)
- Encorafenib plus binimetinib in patients with BRAFV600-mutant non-small cell lung cancer: Phase II PHAROS study design. (2021) (3)
- 61OOUTCOME OF SURGICAL SALVAGE FOR LOCAL FAILURES FOLLOWING STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) (2015) (3)
- Pharmacokinetic boosting of osimertinib with cobicistat in patients with non-small cell lung cancer: The OSIBOOST trial. (2022) (2)
- Is the routine use of trimodality therapy for selected patients with non-small cell lung cancer supported by long-term clinical outcomes? (2016) (2)
- 478TiPA phase II, multicenter, four-cohort study of oral cMET inhibitor capmatinib (INC280) in patients with EGFR wild-type, advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease (2015) (2)
- Prevalence and clinical association of MET gene amplification in patients with NSCLC: results from the ETOP lungscape project (2015) (2)
- Brigatinib in Crizotinib-Refractory ALK plus NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial (2017) (2)
- Brigatinib (BRG) in ALK+ crizotinib (CRZ)-refractory non-small cell lung cancer (NSCLC): Final results of the phase 1/2 and phase 2 (ALTA) trials. (2021) (2)
- Response to “Optimized Alectinib Dose Regimen for Treatment of Patients With ALK‐Positive NSCLC Based on Robust Pharmacometric Analyses and Clinical Evidence” (2021) (2)
- Titel resultaat: Power of the past: a randomized controlled trial testing the efficacy (2012) (2)
- A phase II study of carboplatin and vincristine in previously treated patients with small-cell lung cancer (2004) (2)
- Benefit of a Second Opinion for Lung Cancer: No Metastasis to the Kidney but a Synchronous Primary Renal Neoplasm (2014) (2)
- Multidisciplinary Team Management of Lung Cancer (2007) (2)
- Effects of Tracer Uptake Time in Non–Small Cell Lung Cancer 18F-FDG PET Radiomics (2021) (2)
- An 82-year-old woman with small-cell lung cancer: relapse after 9 years or a new primary? (2012) (2)
- LBA45 Primary data from DESTINY-Lung01: A phase II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC) (2021) (2)
- Exposure–Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life Setting (2022) (2)
- Whole body PD-L1 PET in patients with NSCLC and melanoma. (2018) (2)
- Pituitary gland: do anticancer drugs sit in the Turkish saddle? (2014) (2)
- Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial. (2022) (2)
- The Diagnosis of Tumors. (1946) (2)
- Abstract 3244: Role of epithelial-mesenchymal transition (EMT) in sensitivity to CNX-2006, a novel mutant-selective EGFR inhibitor which overcomes in vitro T790M-mediated resistance in NSCLC. (2013) (2)
- Non-small cell lung cancer, early stage (2012) (2)
- 1347P Health-related quality of life (HRQoL) in patients (pts) with NSCLC harboring MET exon 14 skipping (METex14) treated with tepotinib (2020) (2)
- Benefit of a second opinion: From metastatic disease to resectable lung cancer with sarcoid-like reaction (2014) (2)
- Abstract A029: Biomarker analysis of patients withMETΔex14 mutated non-small-cell lung cancer (NSCLC) treated with capmatinib in the GEOMETRY mono-1 study (2019) (2)
- Pemetrexed versus pemetrexed plus carboplatin in pretreated patients with advanced non-small cell lung cancer (NSCLC): Pooled analysis of two randomized trials. (2011) (2)
- 614 The proteomic classifier VeriStrat® identifies advanced non small cell lung cancer (NSCLC) patients gaining clinical benefit from treatment with first line sorafenib and erlotinib (2010) (2)
- Evaluation of Cost-effectiveness of FDG-PET in Non-Small Cell Lung Cancer. (2006) (2)
- A phase 1 B, open-label, dose-escalation study of bortezomib (Btz) in combination with gemcitabine (G) and cisplatin (C) in the first-line treatment of patients with advanced solid tumors: preliminary results (2005) (2)
- Study of 89 Zr-Pembrolizumab PET/CT in Patients With Advanced-Stage Non – Small Cell Lung Cancer (2022) (2)
- A potential clinical PET tool for quantitative imaging of activating EGFR mutations in non small cell lung carcinoma (2011) (2)
- MA 05.07 Whole Body PD-1 and PD-L1 PET in Pts with NSCLC (2017) (2)
- FP14.09 Tepotinib Safety in MET Exon 14 (METex14) Skipping NSCLC: Updated Results from the VISION Trial (2021) (2)
- Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLC (2021) (2)
- Nonsmall-cell cancers of the lung : Pathology and genetics (2018) (2)
- Stereotactic radiotherapy or surgery for early-stage non-small-cell lung cancer - Authors' reply. (2016) (2)
- Power of the past: a randomized controlled trial to assess effectiveness of life review therapy in palliative cancer patients (2014) (2)
- IV Different right ventricular contractility in limited cutaneous systemic sclerosis-associated pulmonary arterial hypertension and idiopathic pulmonary arterial hypertension (2010) (2)
- Impact of reconstruction algorithms on the repeatability of various PET/CT radiomics features in lung cancer patient (2015) (2)
- Real-world costs of laboratory tests for non-small cell lung cancer (2015) (2)
- OLIGOMETASTATIC NON-SMALL CELL LUNG CANCER: A SIMULATION EXPERT MULTIDISCIPLINARY TUMOR BOARD (2013) (2)
- Fast, Sensitive and Accurate Egfr and K-Ras Mutation Screening Using High Resolution Melting (Hrm) (2009) (2)
- D7-03: A phase II study of erlotinib (E) and bevacizumab (B) in patients (pts) with previously untreated stage IIIB/IV non-small-cell lung cancer (NSCLC) (2007) (2)
- The European Thoracic Oncology Platform Lungscape project: Clinical outcome data as a basis for molecular correlations in resected non-small cell lung cancer. (2013) (2)
- Pembrolizumab in Small-Cell Lung Cancer: In Search of the Best Biomarker. (2017) (1)
- Parametric Method Performance for Dynamic 18F-FLT PET/CT in EGFR-mutated NSCLC Patients prior and during Therapy (2016) (1)
- Identifying NSCLC patients who 1 benefit from afatinib therapy using [F-18]afatinib PET/CT (2019) (1)
- P-226 Multicentre phase II trial of accelerated high dose epirubicin and cisplatin followed by surgery in patients with locally advanced non-small cell lung cancer (2005) (1)
- Abstract 176: Kinase activity of tumor-derived exosomes as a potential biomarker for response to treatment (2012) (1)
- Minimally invasive lobectomy versus stereotactic ablative radiotherapy for stage I non-small cell lung cancer. (2022) (1)
- P2.03-058 Tiger-3: A Phase 3 Randomized Study of Rociletinib Vs Chemotherapy in EGFR-mutated Non-small Cell Lung Cancer (NSCLC) (2017) (1)
- PL2-03: New imaging techniques (PET, PET/CT, MRI, E(B)US.) for lung cancer staging and response assessment (2007) (1)
- O13-3 Tepotinib in patients with MET exon 14 (METex14) skipping advanced NSCLC: Updated efficacy results from VISION cohort A (2021) (1)
- CD133+hematopoietic progenitor cells in non-small cell lung cancer patients as indicator of an anti-angiogenic therapeutic response (2009) (1)
- [Treatment and prognosis of superior sulcus tumours]. (2012) (1)
- Detection of Circulating Tumor Cells Using the Attune NxT (2022) (1)
- P193b A DOUBLE BLIND RANDOMIZED CONTROLLED TRIAL ON ORAL NUTRITIONAL SUPPLEMENTATION OF OMEGA-3 FATTY ACIDS IN NON-SMALL CELL LUNG CARCINOMA (2008) (1)
- 110PDSINGLE ORGAN METASTATIC DISEASE, A NEW PROGNOSTIC FACTOR FOR OVERALL SURVIVAL (OS) IN STAGE IV NON-SMALL CELL LUNG CANCER (NSCLC) (2015) (1)
- Whole brain radiotherapy with concurrent erlotinib for brain metastases from non-small cell lung cancer: A phase I study (2008) (1)
- MA19.08 Detection of Primary Immunotherapy Resistance to PD-1 Checkpoint Inhibitors (PD1CI) in 2nd Line NSCLC (2018) (1)
- Does drug accumulation in bone explain the efficacy and toxicity of docetaxel in prostate cancer? (2014) (1)
- Clinical recommendations for EGFR mutation testing in non-small cell lung cancer (NSCLC): Results from a European workshop. (2010) (1)
- How should "RET positive" NSCLC be treated? (2017) (1)
- P84 Response monitoring with positron emission tomography (PET) in patients with advanced non-small-cell lung cancer (NSCLC) treated with bevacizumab and erlotinib: a phase II study (2007) (1)
- Abstract LB056: Accurate detection ofMETexon 14 skipping using a liquid biopsy assay in NSCLC patients in the GEOMETRY mono-1 study (2021) (1)
- NSCLC Patients With Brain Metastases Treated With Platinum-Based Doublets as First-Line Therapy: Analyses From the European FRAME Observational Study (2014) (1)
- Retrospective analysis of type of KRAS mutation (mut) and response to first-line platinum-based chemotherapy (PC) in non-small cell lung cancer (NSCLC) patients (pts). (2014) (1)
- Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study. (2022) (1)
- TIGER-3: A phase 3 multinational open-label randomized study of rociletinib vs investigator-choice chemotherapy in patients (pts) with epidermal growth factor receptor mutant-positive (EGFRm) non-small cell lung cancer (NSCLC) progressing on prior EGFR tyrosine kinase inhibitor (TKI) therapy and dou (2016) (1)
- Randomised phase 3 study of adjuvant chemotherapy with or without nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 study (2019) (1)
- Is pneumonectomy justifiable for patients with a locoregional recurrence or persistent disease after curative intent chemoradiotherapy for locally advanced non-small cell lung cancer? (2020) (1)
- Randomized phase III study of docetaxel versus docetaxel plus intercalated erlotinib in patients with relapsed non-squamous non-small cell lung carcinoma. (2021) (1)
- MA 17.10 Toxicity Results from the Randomized Phase III NVALT-11 Study of Prophylactic Cranial Irradiation vs. Observation in Stage III NSCLC (2017) (1)
- The influence of fluticasone inhalation on premalignant lesions in the bronchial epithelium of a high risk population: A double blind placebo-controlled randomised phase II study. (2006) (1)
- P-795 Phase III study comparing cyclophosphamide, doxorubicin, and etoposide (CDE) to carboplatin and paclitaxel (CP) in patients (pts) with extensive disease small cell lung cancer (ED SCLC) (2005) (1)
- CT-guided pulmonary radiofrequency ablation. (2008) (1)
- [EGFR-mutation in non-small cell lung carcinoma. Treatment with tyrosine kinase inhibitors possible]. (2011) (1)
- 71POUTCOME AFTER SBRT FOR POTENTIALLY OPERABLE NSCLC PATIENTS (2015) (1)
- A phase II study of erlotinib (E) and bevacizumab (B) in chemo naive patients (pts) with locally advanced or metastatic non small cell lung cancer (NSCLC) : Predictive value of molecular imaging (2008) (1)
- Acquired ocular toxoplasmosis in a patient with thymoma (2015) (1)
- Pan-HER inhibition in EGFR wild-type non-small-cell lung cancer. (2014) (1)
- Chemotherapy in KRAS-mutated chemotherapy naive non-small cell lung cancer patients: A phase III comparing cisplatin-pemetrexed with carboplatin-paclitaxel-bevacizumab: NVALT 22 (NCT02743923). (2019) (1)
- Detecting resistance in EGFR-mutated non-small-cell lung cancer after clonal selection through targeted therapy. (2015) (1)
- University of Groningen Repeatability of Radiomic Features in Non-Small-Cell Lung Cancer [F-18]FDG-PET/CT Studies (2016) (1)
- 1305PDWhole body PD-1 and PD-L1 PET in pts with NSCLC (2017) (1)
- PS01.60: Ph Ib/II, Trial of INC280 ± Erlotinib vs Platinum + Pemetrexed in Adult pts with EGFR‐Mutated, cMET amplified, EGFR TKI Resistant, Advanced NSCLC: Topic: Medical Oncology (2016) (1)
- Comment on Cho et al.: Usefulness of FDG PET/CT in determining benign from malignant endobronchial obstruction (2011) (1)
- Expression of thymidylate synthase (TYMS) and Insulin growth factor 1 (IGF1) in completely-resected NSCLC patients: associations with histological subtype and prognosis (2009) (1)
- [Role of chemo(radio)theray prior to surgery for stage IIIa non-small cell lung carcinoma (localized non-resectable tumor)]. (1999) (1)
- Failure patterns of combined modality treatment in lung cancer: the impact of staging. (2002) (1)
- Etoposide and mesothelioma. (1990) (1)
- Genomic subtypes of pulmonary large cell neuroendocrine carcinoma (LCNEC) may predict chemotherapy outcome (2017) (1)
- ROLE OF POSITRON EMISSION TOMOGRAPHY IN STAGING OF LUNG CANCER (2001) (1)
- 2OExpanding the use of approved drugs: The CPCT’s Drug Rediscovery Protocol (DRUP) (2017) (1)
- Re: Sarcoid-like reaction to malignancy on whole-body integrated 18F-FDG PET/CT: prevalence and disease pattern. (2010) (1)
- O13-4 Tepotinib safety in MET exon 14 (METex14) skipping NSCLC: Updated results from the VISION trial (2021) (1)
- 4IN ESMO RECOMMENDATION 2011: ADVANCED NSCLC (2011) (1)
- 399P Real-world insights into patients (pts) with advanced NSCLC and MET alterations (2020) (1)
- Analysis of serious weight gain in patients using alectinib for ALK positive lung cancer. (2023) (1)
- Critical factors for patient management. (2003) (1)
- Drug Rediscovery Protocol: Expanded use of existing anticancer drugs (2019) (1)
- O-085 Phase III trial of the protein kinase C α (PKCα) antisense oligonucleotide Aprinocarsen plus gemcitabine/cisplatin versus gemcitabine/cisplatin alone in advanced stage non-small cell lung cancer (NSCLC): Updated results of a randomized phase III trial (2005) (1)
- Afatinib (A) plus cetuximab (C) in the treatment of patients (pts) with NSCLC : The story so far (2017) (1)
- 6510 ORAL Erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): interim results from the European subpopulation of the open-label TRUST study (2007) (1)
- Crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): A European phase II clinical trial–Updated report on progression-free and overall survival. (2019) (1)
- Non-small cell lung cancer and health-related quality of life (HRQOL): Is baseline HRQOL of prognostic value for survival? (2005) (1)
- Pharmacotherapy for treatment of lung cancer in the elderly (2015) (1)
- P87 Dynamic contrast-enhanced MRI (DCE-MRI) as imaging biomarker in non-small cell lung cancer (NSCLC) (2007) (1)
- 48O TREATMENT OF MULTIPLE PRIMARY LUNG CANCERS (MLPC) WITH STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) (2013) (1)
- AParallel Dose-Escalation Study ofWeekly andTwice-Weekly Bortezomib in Combinationwith Gemcitabine and Cisplatin in the First-LineTreatment of Patients with Advanced SolidTumors (2007) (1)
- Multicenter phase II trial of accelerated cisplatin and high-dose epirubicin followed by surgery or radiotherapy in patients with stage IIIa non-small-cell lung cancer with mediastinal lymph node involvement (N2-disease) (2006) (1)
- Prevention of Chemotherapy-induced Myelosuppression in SCLC patients treated with the Dual MDMX/MDM2 Inhibitor ALRN-6924 (2020) (1)
- Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials (2022) (1)
- 1415TiP INSIGHT 2: Tepotinib + osimertinib in patients (pts) with EGFR-mutant NSCLC having acquired resistance to first-line osimertinib due to MET amplification (METamp) (2020) (1)
- The role of surgery in the treatment of oligoprogression after systemic treatment for advanced non-small cell lung cancer. (2021) (1)
- Sorafenib in Non-Small Cell Lung Cancer—Results of Clinical Trials (2013) (1)
- A nonresponding small cell lung carcinoma. (2009) (1)
- Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice (2021) (1)
- 56O OUTCOMES OF CONCURRENT CHEMO-RADIOTHERAPY FOR LARGE-VOLUME STAGE III NSCLC (2013) (0)
- 1283P Predicting the differential diagnosis of pneumonitis in stage IV non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs) by combining clinical and radiomic features (2021) (0)
- Evaluation of cytotoxic therapy in lung cancer using PET with L-[1-C-11]-tyrosine (TYR). (1996) (0)
- Interobserver variability of image derived input functions for noninvasive pharmacokinetic analysis of PET studies (2014) (0)
- Pemetrexed induced thymidylate synthase inhibition in non-small cell lung cancer (NSCLC) in vivo: A pilot study with [18F]FLT PET and clinical outcome (2012) (0)
- Diagnose van tumoren (2002) (0)
- Contents Vol. 96, 2019 (2019) (0)
- Survey of European lung cancer evaluating choice of treatment and tolerability in observed 2nd line NSCLC (SELECTTION): cluster analysis of baseline results (2009) (0)
- Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC) (2023) (0)
- 156: Quality of Life Following Stereotactic Ablative Radiotherapy for Early Stage Lung Cancer: Results from the Rosel Randomized Controlled Trial and a Systematic Review (2016) (0)
- Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer (2023) (0)
- TRLS-03. Intracranial activity of tepotinib in patients with MET exon 14 (METex14) skipping NSCLC enrolled in VISION (2021) (0)
- Title : Effects of tracer uptake time in non-small cell lung cancer 18 F-FDG PET radiomics Running title : Effects of time on NSCLC PET radiomics (2021) (0)
- Validation of parametric analysis of dynamic [18F]FLT PET in EGFR-mutated NSCLC patients prior and during therapy. (2015) (0)
- 52 – Treatment of Extensive-Stage Small Cell Lung Cancer (2018) (0)
- MO01.21 Phase 2 GEOMETRY Mono-1 Study: Capmatinib in Patients with METex14-mutated Advanced Non-Small Cell Lung Cancer who Received Prior Immunotherapy (2021) (0)
- 576 In vivo pharmacokinetics of [11C]docetaxel in lung cancer patients (2010) (0)
- Drug pathway-associated gene polymorphisms in patients with advanced non-small cell lung cancer receiving first-line platinum-gemcitabine combination chemotherapy: A prospective multicenter observational study. (2011) (0)
- Aldehyde Dehydrogenase Activity (ALDH) is higher in normal Hematopoietic Stem Cells compared to Leukemic Stem Cells in Acute Myeloid Leukemia (2012) (0)
- Mediastinal staging of NSCLC and 18FDG PET: M14-01 (2007) (0)
- A Prospective Multicenter Study for ALK IHC plus Metastasized NSCLC (2015) (0)
- small improvement over best supportive care in clinical outcome should be expected. (2014) (0)
- Plasma to blood ratio derived parent fractions for robust plasma input based kinetic analysis of dynamic 18F-FLT PET studies in NSCLC cancer patients (2017) (0)
- Treatment and survival of non-small cell lung cancer patients in the Netherlands (2015) (0)
- MO01.48 INSIGHT 2: Tepotinib + Osimertinib in EGFR-Mutant NSCLC with Resistance to 1st-Line Osimertinib due to MET Amplification (2021) (0)
- Lung cancer. (2003) (0)
- Methodological considerations in full kinetic analysis of [18F]FLT PET in patients with non-small cell lung cancer (2013) (0)
- D6-07: A seventy two gene signature and survival in completely-resected non-small-cell lung cancer (NSCLC) (2007) (0)
- The impact of disease labels on disease experience in patients with prolonged incurable cancer. (2018) (0)
- Abstract 3635: A retrospective evaluation of metformin usage in patients with small cell lung cancer (SCLC). (2013) (0)
- Computed tomography-based radiomics for the differential diagnosis of pneumonitis in stage IV non-small cell lung cancer patients treated with immune checkpoint inhibitors. (2023) (0)
- Molecular imaging of NSCLC (2007) (0)
- KRAS mutated non-small cell lung cancer : a distinct disease entity? (2013) (0)
- Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology (2014) (0)
- Pre-treatment EGFR mutation analysis predicts clinical outcome in a retrospective analysis of 24 non-squamous non-small-cell lung cancer (NSCLC) patients treated with second line afatinib. (2013) (0)
- Evaluation of the effect of sampling of spontaneous sputum over a prolonged period on the sensitivity for lung cancer (2011) (0)
- Salvage Surgery for Local Failures after Stereotactic Ablative Radiotherapy for Lung Malignancies (2015) (0)
- Cancer therapy with the proteasome inhibitor Bortezomib and the death ligand TRAIL for Non-Small Cell Lung Cancer (2006) (0)
- Dynamic contrast-enhanced ct in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method to monitor treatment? (2010) (0)
- MO01.45 Health-Related Quality of Life (HRQoL) in Patients with NSCLC Harboring MET Exon 14 Skipping (METex14) Treated with Tepotinib (2021) (0)
- Journal Pre-proof Tobacco smoking related mutational signatures in classifying smoking associated and non-smoking associated non-small cell lung cancer. (2022) (0)
- Diagnostics and Treatment of Patients with Non-Small-Cell Lung Cancer in Daily Practice (2011) (0)
- P1.09-21 Tumor Responses Based on Tumor Growth Rate During PD-1 Inhibitor Therapy in Advanced Non-Small-Cell Lung Cancer Patients (2019) (0)
- 155 Sorafenib Synergizes with the Antidiabetic Drug Metformin in Non-Small Cell Lung Cancer (NSCLC) (2012) (0)
- Reproducibility of 'metabolically active volume' measurements with 18F-FDG and 18F-FLT PET (2009) (0)
- Smoking cessation in volunteers for a chemoprevention study: P1-048 (2007) (0)
- Abstract 4584: High PD-1 expression on regulatory and effector T cells in lung cancer draining lymph nodes (2017) (0)
- 1420TiP A phase I/II trial of radium-223 (Ra-223) in combination with pembrolizumab in patients (pts) with stage IV non-small cell lung cancer (NSCLC) (2020) (0)
- 22O REBIOPSY IN TKI-RESISTANCE: A RETROSPECTIVE ANALYSIS (2013) (0)
- Allowance of tumor-educated platelets for multiclass liquid biopsy-based diagnosis of cancer (2015) (0)
- Abstract #5432: VEGF(R)-targeted treatment specific increase of circulating endothelial cells in non-small-cell lung cancer patients (2009) (0)
- Cisplatin/Gemcitabine followed by Cisplatin/Etoposide and concurrent thoracic radiotherapy in patients with irresectable or medically inoperable non-small-cell lung cancer: P2-203 (2007) (0)
- Does change in health-related quality of life (HRQoL) score predict survival? Analysis of a lung cancer RCT. (2012) (0)
- The introduction of PET in clinical oncology: evaluation in non-small cell lung cancer. (2005) (0)
- Stepped care targeting psychological distress in head and neck and lung cancer patients: a randomized clinical trial (2012) (0)
- Abstract PR5: A phase II study of sorafenib in patients with stage IV non-small cell lung cancer (NSCLC) with a K-Ras mutation (2012) (0)
- Can SUVpeak derived from PSF 18F-PET/CT images act as a surrogate for SUVmax derived from EARL compliant reconstructions? (2018) (0)
- Synchronous Brain Metastases from Non-Small Cell Lung Cancer: Time for Reappraisal of Extracranial Treatment Options? (2010) (0)
- Response prediction by MALDI-TOF-MS serum peptide profiling of combination treatment with sorafenib and erlotinib in patients with non-small cell lung cancer. (2012) (0)
- Abstract 5225: Pemetrexed induced thymidylate synthase inhibition in non-small cell lung cancer in vivo: a pilot study with18F-FLT PET: (2010) (0)
- Importance of tumour volume and histology in trimodality treatment of patients with Stage IIIA non-small cell lung cancer—results from a retrospective analysis (2021) (0)
- A04Brigatinib (BRG) in Crizotinib (CRZ)-Refractory ALK+ Non–Small Cell Lung Cancer (NSCLC): efficacy and safety results from ALTA, a pivotal randomized phase 2 Trial (2016) (0)
- Concurrent Chemoradiation, Adjuvant Durvalumab, and KEAP-1/NRF-2 Mutations: A Happy Marriage? (2021) (0)
- Brigatinib in crizotinib-refractory ALK+ non-small cell lung cancer (NSCLC): efficacy updates and exploratory analysis of target lesion response by baseline brain lesion status in the ALTA Trial (2019) (0)
- [Positron emission tomography in the Netherlands: need to expand the capacity]. (2002) (0)
- Abstract 340: Predictive value of KRAS mutations in advanced non-small cell lung cancer (NSCLC) patients (pts) treated with chemotherapy (CT) (2011) (0)
- CN2 ECONOMIC EVALUATION OF NEW POLY-CHEMOTHERAPY REGIMENS AS ALTERNATIVES TO CISPLATIN PLUS PACLITAXEL IN ADVANCED NON-SMALL CELL LUNG CANCER (2002) (0)
- Abstract 3785: Human pharmacokinetics (PK) of selected tyrosine kinase inhibitors (TKI) in relation to transport characteristics in a polarized gut epithelium model system (2012) (0)
- A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung Cancer. (2023) (0)
- Prognostic factors in patients enrolled in clinical trials of second-line chemotherapy for advanced non-small cell lung cancer (aNSCLC): A pooled analysis of 11 randomized trials. (2009) (0)
- AUTHORS' REPLY (1994) (0)
- Effective generation of tumor-infiltrating lymphocyte products from metastatic non-small-cell lung cancer (NSCLC) lesions irrespective of location and previous treatments (2022) (0)
- Second opinion in expertcentrum zinvol (2012) (0)
- Abstract A31: Predictive and prognostic value of KRAS mutations in advanced non-small cell lung cancer (NSCLC) patients treated with chemotherapy (2012) (0)
- 1447 POSTER First-line Treatment of Non-Small Cell Lung Cancer Under Routine Conditions: Observational Study (FRAME) (2011) (0)
- Reply To Peng et al. (2022) (0)
- Capmatinib efficacy in patients with NSCLC identified as METex14 using an NGS-based liquid biopsy assay: Results from the GEOMETRY mono-1 study. (2021) (0)
- PD-045 Quality assurance review of thoracic radiotherapy inEORTC 08941: A randomized trial of surgery (S) versus thoracic radiotherapy (RT) in patients (pts) with stage IIIA non-small-cell lung cancer (NSCLC) after response to induction chemotherapy (ICT) (2005) (0)
- Preventie en therapie van tumoren (2002) (0)
- A patient with fatigue and subfebrile temperature. (2000) (0)
- Comparison of 15O-H2O PET perfusion studies using an ECAT Exact HR+ stand-alone PET and a Gemini TF PET/CT system (2011) (0)
- Serum peptide profiling in non-small cell lung cancer patients treated with sorafenib and erlotinib: signature discovery (2013) (0)
- Evaluation of FDG PET in the diagnosis and multimodality treatment of stage IIIA-N2 non-small cell lung cancer (NSCLC) (2004) (0)
- Early Response Monitoring of Erlotinib and Sorafenib by 18F-Fluorodeoxygluose and 15O-Water Positron Emission Tomography in Non-Small Cell Lung Cancer (2010) (0)
- Management of extensive-disease small cell lung cancer (2009) (0)
- CHAPTER 6 METABOLIC ACTIVITY MEASURED BY FDG PET PREDICTS PATHOLOGIC RESPONSE IN LOCALLY ADVANCED SUPERIOR SULCUS NSCLC (2014) (0)
- Paclitaxel a nd C arboplatin i n t he T reatment of S mall-Cell L ung C ancer P atients R esistant to C yclophosphamide , D oxorubicin, a nd Etoposide: A N on-Cross-Resist ant S chedule (1999) (0)
- The mutuality and robustness of radiomics features in [18F]FDG PET/CT lung cancer studies (2015) (0)
- P-571 Gemcitabine and cisplatin in patients with resistant small cell lung cancer; a phase II study (2003) (0)
- Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors (2018) (0)
- Chapter 7 Towards prediction of efficacy of chemotherapy : a proof of concept study in lung cancer using [ 11 C ] docetaxel and positron emission tomography (2012) (0)
- Lung cancer. (2001) (0)
- Whole Genome Sequencing in Personalized Oncology - Poster (2017) (0)
- Abstract 2488: Novel candidate protein biomarkers for cisplatin response prediction in non-small cell lung cancer. (2013) (0)
- Overweight and weight loss during chemoradiotherapy are associated with shorter survival after surgery in stage III Non-Small-Cell Lung Cancer (2009) (0)
- A phase II study of erlotinib (E) and bevacizumab (B) in chemo naive patients (pts) with locally advanced or metastatic non small cell lung cancer (NSCLC) (2008) (0)
- A text-mining approach to study the real-world effectiveness and potentially fatal immune-related adverse events of PD-1 and PD-L1 inhibitors in older patients with stage III/IV non-small cell lung cancer (2023) (0)
- A phase I/II study of intensified cisplatin and high dose epirubicin with G-CSF support in patients with relapsed non-small cell lung cancer (2000) (0)
- Comparison of outcome after first-line chemotherapy treatment in types of KRAS mutated lung cancer (2016) (0)
- A population based analysis of outcome of chemotherapy for metastatic pulmonary large cell neuroendocrine carcinomas: does the regimen matter? (2016) (0)
- Correction: Clonality analysis of pulmonary tumors by genome-wide copy number profiling (2019) (0)
- Tumor-educated platelets allow for multiclass liquid biopsy-based diagnosis of cancer (2015) (0)
- Results of neoadjuvant chemo(radio)therapy and resection for stage IIIA non-small cell lung cancer in The Netherlands (2020) (0)
- Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer (2018) (0)
- Comprehensive genetic analysis of typical and atypical lung carcinoids by ArrayCGH (2009) (0)
- Prevention and therapy of tumors (2002) (0)
- CHAPTER 8 B Treatment with high-dose , weekly erlotinib in EGFR-mutated NSCLC-patients with extra-cranial progressive disease on standard-dose EGFR-TKIs (2016) (0)
- Abstract 4388: Genome-wide siRNA screens identify potent p53 inhibitors in NSCLC cells. (2013) (0)
- Retrospective validation of a pretreatment serum protein profile in metastatic non-small cell lung cancer patients treated with a pembrolizumab containing regime as first line of treatment. (2021) (0)
- RCT of first-line TKI versus intercalated TKI with chemotherapy for EGFR mutated NSCLC (2022) (0)
- Contents Vol. 97, 2019 (2019) (0)
- Aspects of palliative chemotherapy for lung cancer (1990) (0)
- PP053-SUN THE PREVALENCE AND PROGNOSTIC VALUE OF PRE-CACHEXIA AND CACHEXIA AT DIAGNOSIS OF STAGE III NSCLC (2011) (0)
- Update on the systemic treatment of lung cancer. (2002) (0)
- Neo-adjuvant therapy for localized NSLC (2001) (0)
- The impact of tumor cavitations on objective and metabolic response assessment in a phase II study of erlotinib and sorafenib in patients with advanced non-small cell lung cancer (NSCLC) (2009) (0)
- Reply to L.H. de Lima Araújo et al (2010) (0)
- Salvage Therapy in Small Cell Lung Cancer (2004) (0)
- EGFR MUTATED PATIENTS: DIFFERENT PATTERN AND OUTCOME OF METASTATIC BONE DISEASE AND BRAIN METASTASES? (2013) (0)
- Tepotinib in patients (pts) with NSCLC with MET exon 14 (METex14) skipping: Health-related quality of life (HRQoL). (2020) (0)
- DNA copy number alterations in squamous metaplastic lesions predict lung cancer (2011) (0)
- PET/CT based imaging biomarkers for response prediction of stage IV NSCLC treated with paclitaxel–carboplatin–bevacizumab with or without nitroglycerin: 158P (2016) (0)
- Analysis of patients with relapsed small cell lung cancer (SCLC) receiving single-agent lurbinectedin in the phase 3 ATLANTIS trial. (2022) (0)
- PD-1 T TILs as a predictive biomarker for clinical benefit to PD-1 blockade in 1 patients with advanced NSCLC 2 (2022) (0)
- Salvage surgery for local failures after stereotactic ablative radiotherapy for early stage non-small cell lung cancer (2016) (0)
- Quality of Life Following Stereotactic Ablative Radiation Therapy Versus Surgery for Early-Stage Lung Cancer : Results From the ROSEL Randomized Controlled Trial and a Systematic Review (2016) (0)
- Benefit of a second opinion for lung cancer: no recurrent disease, but infection. (2012) (0)
- Oral etoposide for a 95-year-old patient with small cell lung cancer. (1989) (0)
- Different toxicity rating patients and physicians in randomized phase III PCI vs obs stage III NSCLC (2018) (0)
- A phase II study of weekly docetaxel/cisplatin and concurrent radiotherapy followed by surgery in patients with stage III non-small cell lung cancer (NSCLC): P2-197 (2007) (0)
- [New data presented at ASCO 2002 concerning small cell bronchial cancer]. (2002) (0)
- A patient perspective on shared decision making in stage I non-small cell lung cancer: a mixed methods study (2015) (0)
- PET imaging of [11C]docetaxel uptake and tumor perfusion in lung cancer. (2010) (0)
- Upfront Resection of Locally-Advanced And/Or Cavitating Nsclc Followed by Chemoradiotherapy (and Adjuvant Systemic Treatment); Phase 1 Multicenter Study to Assess Treatment Feasibility and Safety (NVALT32/UPLAN-I Trial) (2023) (0)
- New insights into acquired resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor therapy in lung cancer. (2019) (0)
- 99P The optimal treatment for patients with stage I non-small cell lung cancer: Minimally invasive lobectomy or stereotactic ablative radiotherapy? (2023) (0)
- 1261P Trastuzumab/pertuzumab combination therapy in advanced pre-treated HER2-mutated non-small cell lung cancer: Results of a DRUP trial cohort (2021) (0)
- 1045P Comprehensive genomic profiling to guide immunotherapy in lung cancer (2022) (0)
- SYST-06 INTRACRANIAL ACTIVITY OF TEPOTINIB IN PATIENTS WITH MET EXON 14 (METEX14) SKIPPING NSCLC ENROLLED IN VISION (2022) (0)
- Multi-Institutio nal R andomized P hase I I T rial o f G efitinib f or Previously T reated P atients W ith A dvanced N on-Small-Cell Lung C ancer (2003) (0)
- Pulmonary Function Changes After Stereotactic Ablative Radiotherapy In 201 Patients With Stage I Non-small Cell Lung Cancer (2011) (0)
- Abstract LB-053: Monitoring rearrangement of EML4-ALK in blood platelets predicts outcome to crizotinib treatment in non-small-cell lung cancer patients (2015) (0)
- Reproducibility of quantitative measurements with [18F]FLT-PET (2008) (0)
- Repeatability of 18F-FDG PET/CT total metabolic active tumor volume and total tumor burden assessment in NSCLC patients: impact of acquisition, image reconstruction and delineation method. (2018) (0)
- P47.09 Tepotinib + Osimertinib for EGFR-Mutant NSCLC with Resistance to First-Line Osimertinib Due to MET amplification: INSIGHT 2 (2021) (0)
- Trastuzumab Deruxtecan in Non-Small-Cell Lung Cancer. Reply. (2022) (0)
- MA26.06 Crizotinib-Treated ALK Immunopositive Metastasized NSCLC is Associated with an Unfavorable Prognosis when FISH Negative (2018) (0)
- Difference in outcome between types of KRAS mutation may point toward difference in tumor biology. (2015) (0)
- Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment (2018) (0)
- Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy (2020) (0)
- Contents Vol. 95, 2018 (2018) (0)
- Pharmacokinetic modelling of PET tracers in oncology (2013) (0)
- Abstract 3885: Peptide-mediated ‘miniprep’ isolation of extracellular vesicles for high-throughput proteomics; method evaluation and application in colon cancer (2016) (0)
- Abstract CT536: Tepotinib efficacy and safety in patients with MET exon 14 (METex14) skipping NSCLC (2022) (0)
- A feasibility study of testing new drugs for small-cell lung cancer in patients with a poor performance status (2004) (0)
- Early response evaluation of PD-1 blockade in NSCLC patients through FDG-PET-CT and T cell profiling of tumor-draining lymph nodes (2023) (0)
- D7-01: 4-dimensional respiration-gated radiotherapy for concurrent chemo-radiotherapy in lung cancer (2007) (0)
- Genomic profiling for risk assessment of preneoplastic endobronchial lesions. (2007) (0)
- Applying biomarker testing to clinical practice in lung cancer (2012) (0)
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer (2022) (0)
- Deletions of 11q21-q25 Are Associated with Atypical Lung Carcinoids and a Poor Clinical Outcome (2010) (0)
- Novel candidate biomarkers for cisplatin response prediction and monitoring in NSCLC (2013) (0)
- Can [F-18]afatinib PET/CT be used in identifying NSCLC patients with different EGFR mutational status: tracer quantification and assessment of tumor uptake (2019) (0)
- 157P Tepotinib in patients (pts) with MET exon 14 (METex14) skipping NSCLC: Efficacy results from all pts enrolled in VISION cohort A (2021) (0)
- One-year data on immunogenicity and breakthrough infections in patients with solid tumors vaccinated against COVID-19 during systemic cancer treatment (2023) (0)
- Abstract 113: A comparative preclinical PET imaging study between [11C]erlotinib and [18F]afatinib (2014) (0)
- Gemcitabine a nd P aclitaxel: P harmacokinetic and P harmacodynamic I nteractions i n P atients With N on-Small-Cell L ung C ancer (1999) (0)
- Mass spectrometric serum peptide profiling for drug response prediction: signature validation (2013) (0)
- Biodistribution and radiation dosimetry of [11C] docetaxel determined using human whole body PET_CT (2009) (0)
- 9122 Phase I study with pemetrexed, cisplatin and concurrent radiotherapy in limited-stage small cell lung cancer (LS-SCLC) (2009) (0)
- p53 immunostaining and hTERT expression in endobronchial premalignant lesions (2000) (0)
- Abstract 5394: Tumor-induced immunological changes in peripheral blood of untreated stage IV non-squamous NSCLC patients (2012) (0)
- 1594P Harmonising patient-access programmes (2020) (0)
- A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma ( EORTC trial 08956 ) 1 (2009) (0)
- Does Surgery Have a Role in the Era of High Dose Chemoradiotherapy for Locally Advanced NSCLC (2011) (0)
- Real-World Costs of Laboratory Tests for Non-Small Cell Lung Cancer. (2014) (0)
- Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer (2022) (0)
- 6513 ORAL A phase II study of erlotinib (E) and bevacizumab (B) in patients (pts) with previously untreated stage IIIB/IV non-small-cell lung cancer (NSCLC) (2007) (0)
- Endoscopic ultrasound guided fine-needle aspiration and FDG-positron emission tomography in the evaluation of patients (2007) (0)
- Lung cancer. (2005) (0)
- Reproducibility of tumor perfusion measurements using [15O]H2O and PET (2008) (0)
- OP62 Polymorphisms in AKT1 and EGFR as possible new biomarkers of clinical outcome and toxicity in non-small-cell lung cancer patients treated with gefitinib (2009) (0)
- ETOP activity in the field of biomarkers and predictors (2012) (0)
- Accuracy and precision of parametric analysis of dynamic [18F]FLT PET in NSCLC patients. (2016) (0)
- Co-expression of polycomb proteins EZH2 and BMI-1 in squamous cell carcinomas of the bronchus (2000) (0)
- Abstract LB-396: Molecular characterization of ED-SCLC: high-resolution SNP 6.0 arrays, mRNA expression, and miRNA arrays from the phase III GALES trial (2012) (0)
- Histopathologic changes due to neo-adjuvant chemoradiotherapy in resected NSCLC (2009) (0)
- Absolute Quantification of [C]docetaxel Kinetics in Lung Cancer Patients Using Positron Emission Tomography (2011) (0)
- CHAPTER 5 Sorafenib in Non-Small Cell Lung Cancer : results of clinical trials (2013) (0)
- Validation of a polymerase chain reaction aided transcript titration assay (PATTY) for topoisomerase II in lung cancer samples. (2000) (0)
- Abstract 487: A high percentage of LCNEC shows DLL3 expression in association with molecular subtypes and neuroendocrine markers (2019) (0)
- CLINICAL STUDY BY THE DUTCH ASSOCIATION OF PULMONOLOGISTS (NVALT) INVESTIGATING THE EARLY IMMUNE TUMOR INTERPLAY DURING CHEMOTHERAPY IN STAGE IV NON-SQUAMOUS NSCLC PATIENTS (2011) (0)
- Tracer kinetic modeling of [11C]docetaxel in lung cancer (2010) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Egbert Frederik Smit?
Egbert Frederik Smit is affiliated with the following schools:
